SEATTLE, August 03, 2021, (MEDGADGET) — Global Respiratory Syncytial Virus Diagnostics Market Analysis

Overview

Many chronic diseases, such as respiratory illness, pneumonia, asthma, and bronchitis, are caused by the RSV (Respiratory Syncytial Virus). It typically affects newborns, babies, and adults, causing outpatient visits, hospitalization, and, in some cases, death. As a result, early detection of RSV-related illnesses is critical to avert additional medical complications.

Rhinorrhea, cough, wheezing, respiratory distress, and hypoxemia are all symptoms of RSV infection. The most frequently utilized approach for detecting RSV is molecular diagnostics.

*The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it.
Download Free PDF Sample: https://www.coherentmarketinsights.com/insight/request-pdf/2038

Drivers

The high frequency of RSV-related respiratory illnesses is a significant factor driving growth of the global respiratory syncytial virus diagnostics market during the forecast period. According to a research published in the Lancet, about 33.1 million episodes of RSV-induced acute lower respiratory infections occurred in children younger than 5 years of age in 2017, resulting in around 3.2 million hospitalizations and 59,600 in-hospital fatalities worldwide in 2015. Furthermore, the study revealed that in 2015, the overall RSV-related mortality was about 118200.

In addition, the high incidence of various chronic diseases caused by RSV, such as pneumonia and other respiratory tract infections, is a key driver propelling the global respiratory syncytial virus diagnostics market expansion during the forecast period. Lower respiratory tract infection and COPD (Chronic obstructive pulmonary disease) are among the top five chronic illnesses with the largest death rate, according to a World Health Organization (WHO) research published in May 2018. According to the research, over 3 million fatalities were recorded worldwide in 2016 owing to COPD and lower respiratory tract infection.

Regional Analysis

During the forecast period, North America is projected to dominate the global respiratory syncytial virus diagnostics market. As per a research published in the journal American Family Physician in 2017, around 2% to 3% of infants less than 12 months are hospitalized in the U.S. each year with a RSV infection. According to the same source, RSV infections cause over 57,500 hospitalizations and 2.1 million outpatient visits in children under the age of five years in the U.S. each year. Epidemiological data suggests that the market for respiratory syncytial virus diagnostics in the U.S. has a lot of potential. Another major driver for market expansion would be the presence of leading competitors and their goods in North America.

The global respiratory syncytial virus diagnostics market will grow at the fastest rate in Asia Pacific and Latin America. As per research published in The Lancet in September 2017, RSV-ALRI caused about 43,600 fatalities in lower-middle-income countries and around 17900 deaths in higher middle-income countries in 2015.

“Limited Time Offer”

Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2038

Additionally, infants in this region are frequently under-vaccinated, resulting in high rates of infection from a number of illnesses, including RSV. As per the World Health Organization (WHO), around 86 percent of newborns worldwide get vaccinated against 26 illnesses in 2018. Meanwhile, around 19.5 million children are still unvaccinated, resulting in approximately 2-3 million fatalities per year, with approximately 90% of these deaths occurring in poor and medium-income nations.

WHO is conducting vaccine pilot programs in developing nations such as Latin America, Africa, and Asia Pacific in order to achieve 100% detection of RSV infections in babies, neonates, and children under the age of five. This is projected to minimize RSV-related acute lower respiratory infection death and hospitalization rates. In these areas, RSV diagnostic centers would be established throughout the forecast period.

Competitive Landscape

Major companies contributing in the global respiratory syncytial virus diagnostics market are Thermo Fisher Scientific Inc., BioMerieux, Novartis AG, Ortho Clinical Diagnostics, Quidel Corporation, Dickinson and Company, Becton, F. Hoffmann La-Roche AG, Quest Diagnostics, Fast-track Diagnostics, Coris BioConcept, Alere Inc., Millipore-sigma, Abbott Laboratories, DiaSorin SPA, and Bio-Rad Laboratories Inc.  

To get a detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/2038

Furthermore, the major companies are concentrating on new product releases in order to increase their market share. In 2016, BD (Becton, Dickinson and Company) released the Veritor Plus, a wireless fast diagnostic device for the detection of RSV, influenza A and B, and group A strep, with improved traceability and secure patient-health record recording capabilities and capability.

Abbott Laboratories finalized the purchase of Alere, Inc. in October 2017, which offers RSV testing systems such as the ALERE I RSV.

Key Developments

The US Food and Drug Administration (FDA) granted QIAGEN N.V. 510 (k) approval for their QIAstat-Dx syndromic diagnostic system in May 2019.

BD (Becton, Dickinson and Company) released the Veritor Plus, a next-generation wireless fast diagnostic device in 2016.

Abbott Laboratories completed the acquisition of Alere, Inc. in 2017, which makes RSV diagnostic systems like the ALERE I RSV.

The Alere I RSV Rapid Molecular Test and Alere Reader Lateral Flow Assay Analyzer were approved by the US Food and Drug Administration (FDA) in 2016 and obtained CLIA exemptions.

Roche Diagnostics obtained CLIA from the US Food and Drug Administration (FDA) in September 2015 for the cobas Liat System’s detection of flu A/B, RSV, and Strep A. The technology may now be utilized in pharmacy facilities, hospitals, physician offices, and other healthcare institutions that have received clearance.

Table of Content

Global Respiratory Syncytial Virus Diagnostics Market Research Report
Section 1: Global Respiratory Syncytial Virus Diagnostics Industry Overview
Section 2: Global Economic Impact on Respiratory Syncytial Virus Diagnostics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Respiratory Syncytial Virus Diagnostics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Respiratory Syncytial Virus Diagnostics Market Forecast

Other Related News:

Duodenoscopes Market – https://www.openpr.com/news/2344339/pdf-worldwide-analysis-on-duodenoscopes-size-and-trends

Neurology Devices Market – https://www.openpr.com/news/2344365/pdf-at-15-9-of-cagr-neurology-devices-market-share-touch-us

Mercury-Free Dental Implants Materials Market – https://www.openpr.com/news/2344398/mercury-free-dental-implants-materials-market-increasing

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837